Application of 2-(2-methylpropoxy)aniline in preparing medicine for treating inflammatory diseases
The natural product 2-(2-methylpropoxy)aniline from marine origin inhibits the expression of inflammatory mediators and enzymes, solving the problems of single targets of existing anti-inflammatory drugs and major toxic side effects, and achieving the goal of inflammatory diseases Effective control provides safe and effective treatment plans.
Patent Information
- Application Number
- CN202410517282.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-28
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-04-28
AI Technical Summary
Existing anti-inflammatory drugs have problems such as single targets, high toxicity and expensive side effects, making it difficult to effectively control the inflammatory response, leading to serious consequences of inflammatory diseases.
Using marine-derived natural product 2-(2-methylpropoxy)aniline as an active ingredient, significantly reduces the release of inflammatory mediator NO, macrophage M1 type polarization, inflammatory enzyme expression and proinflammatory factors. Tissue damage caused by inflammatory mediators.
2-(2-methylpropoxy)aniline efficiently inhibits inflammatory response in a dose-dependent manner in a dose-dependent manner in the range of 10 μM~40 μM, significantly reduces the expression of inflammatory mediators and enzymes, and effectively prevents and repairs the acute in mice caused by LPS stimulation. Lung injury provides safe and effective anti-inflammatory drug solutions.
Smart Images

Figure CN118416038B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of marine biology and medical technology, and specifically relates to the application of 2-(2-methylpropoxy)aniline in preparing medicines for treating inflammatory diseases. Background Art
[0002] Inflammation is a series of physiological processes mainly based on defense that tissues respond to in response to the stimulation of various damaging factors. Although the inflammatory response is important for maintaining the homeostasis of the body's internal environment, excessive inflammatory response can cause serious damage to the human body. When the body is stimulated by exogenous or endogenous stimuli, a large amount of inflammation will occur. If the inflammation is not effectively controlled, it will lead to diseases such as sepsis, pneumonia, rheumatoid arthritis, and atherosclerosis. The anti-inflammatory drugs currently used in clinical practice are mainly small molecule drugs and biological drugs. Small molecule drugs are mainly COX inhibitors and glucocorticoids, and biological drugs are mainly antibody drugs targeting cellular inflammatory factors. However, the above-mentioned drugs have problems such as single target, large toxic side effects, and high prices. Therefore, it is of great significance to develop safe and effective new anti-inflammatory drugs.
[0003] 2-(2-methylpropoxy)aniline (2-Isobutoxyaniline, C10H15NO, CAS No.: 104065-95-4) is an aniline compound derived from marine actinomycetes and exists in Brevibacterium sp. The structure of marine-derived compounds is relatively new and has great development potential. So far, eight marine-derived compounds have been approved for clinical use, five of which are used for cancer treatment. However, the anti-inflammatory effect of 2-(2-methylpropoxy)aniline has not been reported. Summary of the invention
[0004] The purpose of the present invention is to provide the use of 2-(2-methylpropoxy)aniline in the preparation of drugs for treating inflammatory diseases. The present invention has experimentally confirmed that the natural product 2-(2-methylpropoxy)aniline from marine sources has significant anti-inflammatory effects.
[0005] In order to achieve the above-mentioned invention object, the present invention adopts the following technical solutions:
[0006] The invention provides application of 2-(2-methylpropoxy)aniline in preparing medicine for treating inflammatory diseases.
[0007] Furthermore, the 2-(2-methylpropoxy)aniline can significantly inhibit the release of inflammatory mediator NO.
[0008] Furthermore, the 2-(2-methylpropoxy)aniline can effectively inhibit the release of the inflammatory mediator NO in a dose-dependent manner in the range of 10 μM to 40 μM.
[0009] Furthermore, the 2-(2-methylpropoxy)aniline can effectively inhibit LPS-induced macrophage M1 polarization and thus exert an anti-inflammatory effect.
[0010] Furthermore, the 2-(2-methylpropoxy)aniline can effectively reduce the mRNA transcription levels of M1 macrophage polarization markers CD86 and CD80.
[0011] Furthermore, the 2-(2-methylpropoxy)aniline can significantly inhibit the transcription level of iNOS and COX-2 and the protein expression of the key inflammatory enzymes iNOS and COX-2.
[0012] Furthermore, the 2-(2-methylpropoxy)aniline can significantly reduce the expression levels of pro-inflammatory factors TNF-α, IL-6, IL-1β, and IFN-β.
[0013] Furthermore, the inflammatory diseases include acute lung injury, pneumonia, and sepsis.
[0014] The present invention also provides a medicine for treating inflammatory diseases, wherein the medicine contains 2-(2-methylpropoxy)aniline as an active ingredient and pharmaceutically acceptable excipients.
[0015] Furthermore, the content of 2-(2-methylpropoxy)aniline in the drug is 10 μM~40 μM.
[0016] Compared with the prior art, the present invention has the following beneficial technical effects:
[0017] In view of the shortcomings of existing anti-inflammatory drugs, the present invention selects 2-(2-methylpropoxy)aniline, a natural product derived from the ocean, as a research object, and reveals its inhibitory effect on LPS-induced inflammatory response at in vivo and in vitro levels. 2-(2-methylpropoxy)aniline has a good inhibitory effect on LPS-induced inflammatory response, can inhibit macrophage polarization to M1 type, inhibit the expression of inflammatory enzymes, and inhibit the transcription and release of pro-inflammatory factors, reduce tissue damage caused by inflammatory mediators, and thus has a strong anti-inflammatory effect of preventing and repairing LPS-stimulated macrophages, and improves acute lung injury in mice infected with LPS.
[0018] The present invention proves for the first time that 2-(2-methylpropoxy)aniline has the ability to inhibit LPS-induced inflammatory response of RAW264.7 and alleviate LPS-induced lung injury in mice. Therefore, 2-(2-methylpropoxy)aniline can be developed into a new drug for preventing and / or treating inflammation.
[0019] After reading the specific embodiments of the present invention in conjunction with the accompanying drawings, other features and advantages of the present invention will become more clear. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is the result of the detection of the cytotoxic effect of 2-(2-methylpropoxy)aniline and LPS on RAW264.7 cells in Example 1. *p<0.05, **p<0.01, ***p<0.001 are all compared with the Mock group.
[0021] Figure 2 This is the result graph showing that 2-(2-methylpropoxy)aniline can significantly inhibit the release of inflammatory mediator NO induced by LPS in a dose-dependent manner and that 2-(2-methylpropoxy)aniline itself has no effect on the release of inflammatory mediator NO in Example 1. *p<0.05, **p<0.01, ***p<0.001 are all compared with the LPS group.
[0022] Figure 3 This is a graph showing the experimental results of 2-(2-methylpropoxy)aniline inhibiting LPS-induced morphological changes and M1 polarization of RAW264.7 cells in Example 1. *p<0.01, **p<0.001 are compared with the LPS group.
[0023] Figure 4 This is a graph showing the inhibitory effect of 2-(2-methylpropoxy)aniline on the mRNA transcription level and protein expression of iNOS and COX-2 induced by LPS in Example 1. *p<0.01, **p<0.001 are compared with the LPS group.
[0024] Figure 5 This is a graph showing the results of 2-(2-methylpropoxy)aniline inhibiting LPS-induced IL-6 secretion and mRNA transcription levels of TNF-α, IL-6, IL-1β, and IFN-β in Example 1. *p<0.01, **p<0.001 are compared with the LPS group.
[0025] Figure 6 This is a graph showing the experimental results in Example 2 that 2-(2-methylpropoxy)aniline can improve acute lung injury caused by intraperitoneal injection of LPS.
[0026] The marine compound 2-(2-methylpropoxy)aniline is referred to as IBT in all figures, and the positive drug dexamethasone is referred to as DXM in all figures. DETAILED DESCRIPTION
[0027] The technical scheme of the present invention is further described in detail below in conjunction with the accompanying drawings and specific embodiments, but it should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.
[0028] The present invention evaluates the inhibitory effect of 2-(2-methylpropoxy)aniline on LPS-induced inflammatory response according to an internationally recognized method. The 2-(2-methylpropoxy)aniline used in the present invention can be a commercially available product, the CAS No. of the 2-(2-methylpropoxy)aniline is 104065-95-4, and the chemical structure of the 2-(2-methylpropoxy)aniline is as follows:
[0029] .
[0030] Example 1: 2-(2-methylpropoxy)aniline inhibits LPS-induced inflammatory response in vitro
[0031] 1. Cytotoxicity test of 2-(2-methylpropoxy)aniline
[0032] The cytotoxicity of 2-(2-methylpropoxy)aniline to RAW264.7 cells was determined. RAW264.7 cells were seeded in 96-well plates with 1×10 4 cells, 180 μL DMEM high-glucose complete medium was added to each well, and the edges of the 96-well plate were sealed with sterile water. After 24 hours, different doses of 2-(2-methylpropoxy)aniline were mixed with DMEM complete medium (final concentrations were 160 μM, 80 μM, 60 μM, 40 μM, and 20 μM), and 20 μL of the mixed drug was added to each well. Three replicate wells were set for each concentration, and a blank control group was set up at the same time. After culturing at 37℃ 5% CO2 for 24 hours, resazurin was added, 20 μL per well (final concentration 0.2 mg / ml), and the fluorescence value was detected by an enzyme reader after 6 hours.
[0033] The cytotoxicity of 2-(2-methylpropoxy)aniline and LPS on RAW264.7 cells was determined. RAW264.7 cells were seeded in 96-well plates, with 1×10 4 cells, 160 μL DMEM high-glucose complete medium was added to each well, and the edges of the 96-well plate were sealed with sterile water. After 24 hours, different doses of 2-(2-methylpropoxy)aniline were mixed with DMEM complete medium (final concentrations were 160 μM, 80 μM, 60 μM, 40 μM, and 20 μM). Three replicate wells were set for each concentration, and 20 μL of the mixed drug was added to each well. A blank control group was also set up. After culturing at 37°C 5% CO2 for 24 hours, resazurin was added, 20 μL per well (final concentration 0.2 mg / ml), and the fluorescence value was detected by an enzyme reader after 6 hours.
[0034] Cell survival rate = (treatment group - blank group) / (control group - blank group) × 100%;
[0035] The experimental results are as follows Figure 1 As shown in the figure, 2-(2-methylpropoxy)aniline is safe and nontoxic to RAW264.7 cells at 60 μM and below. It is cytotoxic at 80 μM, but the cell viability is still maintained above 60%. When 2-(2-methylpropoxy)aniline and LPS act on RAW264.7 together, the cell activity is above 80% at 80 μM. This shows that 2-(2-methylpropoxy)aniline is less toxic to RAW264.7 cells.
[0036] 2. Griess method to measure the effect of 2-(2-methylpropoxy)aniline on NO release induced by LPS in RAW264.7 cells
[0037] 3×10 cells were seeded per well of a 96-well plate 4 RAW264.7 cells were added to each well. After the cell suspension was mixed with DMEM complete medium, 160 μL of DMEM complete medium was added to each well using a spray gun. After 24 hours, different doses of 2-(2-methylpropoxy)aniline were mixed with DMEM complete medium (final concentrations of 40 μM, 20 μM, and 10 μM), and dexamethasone was mixed with DMEM complete medium (final concentration of 20 μM). Three replicate wells were set for each concentration, and 20 μL of the mixed drug was added to each well. After 2 hours of compound adsorption, LPS was added at a final concentration of 100 ng / ml. After 24 hours, the nitric oxide detection kit was used for detection, and the A540nm value was measured with an enzyme reader. According to the prepared standard curve, the relative content of NO was accurately calculated.
[0038] As an intracellular messenger molecule, NO regulates various cellular functions and participates in the defense of the immune system. Excessive NO secretion can lead to cytotoxicity and mediate the progression of inflammation. The Griess method was used to determine the activity of 2-(2-methylpropoxy)aniline in inhibiting the release of NO from RAW264.7 cells induced by LPS, and the effect of 2-(2-methylpropoxy)aniline itself on the release of inflammatory mediator NO was also determined.
[0039] The experimental results are as follows Figure 2 As shown in the figure, 2-(2-methylpropoxy)aniline can significantly inhibit the release of inflammatory mediator NO induced by LPS in a dose-dependent manner at 10 μM, 20 μM, and 40 μM doses, and the inhibitory effect of 2-(2-methylpropoxy)aniline at 20 μM is the same as that of the positive drug dexamethasone. The IC value of 2-(2-methylpropoxy)aniline for inhibiting NO release is 5O The concentration of 2-(2-methylpropoxy)aniline in the inflammatory medium NO was 14.53 μM, and 2-(2-methylpropoxy)aniline itself had no effect on the release of inflammatory mediator NO. This indicates that 2-(2-methylpropoxy)aniline can effectively inhibit the release of inflammatory mediator NO in a dose-dependent manner, thereby inhibiting the inflammatory response.
[0040] 3. Observation of the effect of 2-(2-methylpropoxy)aniline on the morphology of LPS-induced RAW264.7 cells under an optical microscope
[0041] The experiment was divided into Mock group, LPS group, LPS+compound group, and compound group. 12-well plates were plated, and 16×10 4 RAW264.7 cells were added to each well, and 800 μL of DMEM complete medium cell suspension was added to each well. After overnight culture, the compound + LPS group was given diluted 2-(2-methylpropoxy)aniline (final concentrations of 10 μM, 20 μM, and 40 μM), and the compound group was given 2-(2-methylpropoxy)aniline at a final concentration of 40 μM. 2 h later, the LPS group and LPS + compound group were stimulated with LPS at a final concentration of 100 ng / mL. After 16-20 h, the cell culture medium was removed, 1 mL of pre-warmed PBS was added to each well, and the cell morphology was photographed under a laser confocal microscope.
[0042] LPS can strongly induce RAW264.7 to polarize from M0 to M1. Uncontrolled and continuous polarization of M1 macrophages can damage normal cells and lead to a series of diseases. When the morphology of RAW264.7 macrophages changes from the spherical shape of M0 to the long spindle or sun shape of M1, it means that RAW264.7 macrophages are successfully induced to become M1 pro-inflammatory macrophages.
[0043] The experimental results are as follows Figure 3 As shown in the figure, firstly, the effect of 2-(2-methylpropoxy)aniline on the morphology of RAW264.7 cells induced by LPS was evaluated morphologically. The results showed that 2-(2-methylpropoxy)aniline could effectively reduce the M1 polarization of giant cells induced by LPS, reduce pseudopodia and keratin of RAW264.7 cells, and the inhibitory effect was concentration-dependent. Secondly, the effect of 2-(2-methylpropoxy)aniline on the transcriptional level of M1 macrophage surface markers CD86 and CD80 was evaluated at the transcriptional level. The results showed that 2-(2-methylpropoxy)aniline could effectively inhibit the increase of CD86 and CD80 mRNA levels induced by LPS, and the transcriptional inhibition rate of CD86 was more than 40% at the lowest concentration of 10 μM. This indicates that 2-(2-methylpropoxy)aniline can effectively inhibit the M1 polarization of macrophages induced by LPS, thereby exerting an anti-inflammatory effect.
[0044] 4. qPCR experiments to detect the effects of 2-(2-methylpropoxy)aniline on the transcription level of inflammatory factors and cell polarization induced by LPS
[0045] 12-well plate, 32 × 10 4cells, and 800 μL of DMEM complete medium cell suspension was added to each well. After culturing for 16-24 hours, the cell density reached about 50%-60%, and diluted 2-(2-methylpropoxy)aniline (final concentration of 10 μM, 20 μM, 40 μM) was added to the 12-well plate. After pretreatment for 2 hours, LPS with a final concentration of 100 ng / ml was added to induce RNA for 6 hours or 24 hours (different induction times of LPS). RNA was extracted using the RNA extraction kit of Adele Biotechnology, and RNA was reverse transcribed into cDNA using the Evo M-MLV reverse transcription kit of Acre. qPCR was performed using Roche 480 and Acre SYBR Green Pro Taq HS premixed qPCR reagent. The primer sequences used are shown in Table 1 below.
[0046] Table 1 qPCR primer sequences of RAW264.7 cells
[0047] Gene Sequence(5’→ 3’) IL-6 F CACAGAAGGAGTGGCTAA IL-6 R CCATAACGCACTAGGTTT IL-1β F GGTACATCAGCACCTCAC IL-1β R AAACAGTCCAGCCCATAC INOS F CACGGACGAGACGGATAG INOS R TGCGACAGCAGGAAGG TNFα F CCACCACGCTCTTCTGTCTA TNFα R CTGATGAGAGGGAGGCCATT IFN-β F GGATCCTCCACGCTGCGTTCC IFN-β R CCGCCCTGTAGGTGAGGTTGA COX-2 F GGGCTCAGCCAGGCAGCAAAT COX-2 R GCACTGTGTTTGGGGTGGGCT CD86 F TGTTTCCGTGGAGACGCAAG CD86 R TTGAGCCTTTGTAAATGGGCA β-actin F CACTGTGCCCATCTACGA β-actin R TGATGTCACGCACGATTT
[0048] iNOS and COX-2 are two key rate-limiting enzymes in inflammatory response, inducing the production of inflammatory mediators NO and PGE2, respectively. The activation and expression of iNOS and COX-2 are the hallmark events of cellular inflammatory response. The effect of 2-(2-methylpropoxy)aniline on the transcriptional levels of iNOS and COX-2 was detected by qPCR.
[0049] The experimental results are as follows Figure 4 As shown in the figure, 2-(2-methylpropoxy)aniline can significantly inhibit the transcription levels of iNOS and COX-2 at 6 h and 24 h of LPS stimulation. At 24 h of LPS stimulation, 2-(2-methylpropoxy)aniline showed a concentration-dependent inhibition on the mRNA expression of iNOS and COX-2, and the inhibition rate of iNOS mRNA expression was 60% at a dose of 20 μM, and the inhibition rate of COX-2 mRNA expression was more than 50%. The inhibitory effect of 2-(2-methylpropoxy)aniline on the protein expression of iNOS and COX-2 was further verified by Western blot. It was observed that 20 μM could significantly inhibit the protein expression of iNOS and COX-2 induced by LPS, and the protein bands of iNOS and COX-2 were almost undetectable at 40 μM. This indicates that 2-(2-methylpropoxy)aniline has a strong anti-inflammatory effect on LPS-stimulated macrophages by inhibiting the protein expression of iNOS and COX-2, key enzymes in the inflammatory response, and has a preventive and repairing effect.
[0050] In order to more comprehensively evaluate the anti-inflammatory effect of 2-(2-methylpropoxy)aniline, the present invention further detected the effect of 2-(2-methylpropoxy)aniline on the secretion of IL-6 induced by LPS and the transcription levels of TNF-α, IL-6, IL-1β, and IFN-β. The experimental results are as follows Figure 5 As shown in the results, 2-(2-methylpropoxy)aniline can significantly inhibit the secretion of IL-6 induced by LPS. At 40 μM, the inhibitory effect on IL-6 secretion is better than that of the hormone drug dexamethasone, and the inhibitory effect is dose-dependent. The mRNA expression level of TNF-α was significantly upregulated at 6h and 24h after LPS stimulation, and 2-(2-methylpropoxy)aniline can inhibit the increase of TNF-α transcription level. 2-(2-methylpropoxy)aniline can significantly reduce the mRNA transcription level of IL-6 induced by LPS in a dose-dependent manner. The results show that 2-(2-methylpropoxy)aniline can inhibit the mRNA expression of IL-6 in both the early and late stages of LPS stimulation. At 24h of LPS induction, the inhibition rate of 2-(2-methylpropoxy)aniline at a high dose of 40 μM on the mRNA transcription level of IL-6 reached 84.9%. 2-(2-methylpropoxy)aniline inhibited the mRNA expression of IL-1β in a dose-dependent manner at 24 h of LPS stimulation, and the inhibition rate of IL-1β expression reached 66.24% at a low dose of 10 μM. 2-(2-methylpropoxy)aniline inhibited the transcription of IFN-β in a dose-dependent manner at 6 h and 24 h of LPS stimulation. This shows that 2-(2-methylpropoxy)aniline can inhibit the transcription of inflammatory factors at a low dose and efficiently, thereby exerting an anti-inflammatory effect.
[0051] 5. Western blot test
[0052] When the confluence of RAW264.7 cells reached 80-90%, 70×10 cells were seeded in each well of a 6-well plate. 4 1.6 mL of DMEM complete medium cell suspension was added to each well. After culturing for 16-24 h, the cell confluence reached about 60%. 2-(2-methylpropoxy)aniline (final concentrations of 10 μM, 20 μM, and 40 μM) was pre-administered. After 2 h, LPS at a final concentration of 100 ng / mL was added.
[0053] After 24 hours, the samples were collected, and 80 μL of cell lysis buffer (800 μL RIPA, 200 μL 5× protein loading buffer, 10 μL PMSF) was added to each well. The cells were lysed on ice for 20 min. The lysate was scraped off and transferred to an EP tube. The samples were boiled at 100°C for 20 min and placed in a -20°C refrigerator for later use. The concentration of the extracted protein was determined by BCA kit and then SDS-PAGE electrophoresis was performed. The electrophoresis gel was transferred to a 0.22 μM NC membrane by semi-dry method. The NC membrane was blocked with 5% milk powder at 4°C overnight, washed 3 times with 1× PBST, incubated with iNOS and COX-2 antibody diluent (1:1000 dilution) at 4°C overnight, washed 3 times, and then incubated with secondary antibody diluent (1:5000 dilution) at 37°C for 2 h. The samples were washed 3 times and developed with an alkaline phosphatase detection kit.
[0054] 6. Enzyme-linked immunosorbent assay
[0055] The modeling method was the same as above. The cell supernatant was collected and centrifuged at 1000 xg for 20 min. The supernatant was aliquoted and frozen in a -80°C refrigerator. The detection was performed according to the instructions of Anhui Qiaoyi's mouse IL-6 quantitative analysis enzyme-linked immunosorbent assay kit.
[0056] Example 2: Effect of 2-(2-methylpropoxy)aniline on acute lung injury in mice induced by intraperitoneal injection of LPS
[0057] 1. Experimental groups and drug administration
[0058] All mice used in this case complied with the Guidelines for the Humane Treatment of Laboratory Animals of the Ministry of Science and Technology of China (vgkfcz-2006-398). Six-week-old male C57BL / 6J mice (weight 20 g) were used and randomly divided into 5 groups: blank control group, LPS control group, positive drug dexamethasone group (5 mg / kg / day), 2-(2-methylpropoxy)aniline low-dose group (10 mg / kg / day), and 2-(2-methylpropoxy)aniline high-dose group (20 mg / kg / day). After the mice were adapted to the environment for 5 days, they began to be pre-administered by gavage. The positive drug dexamethasone was administered at 5 mg / kg / day, and 2-(2-methylpropoxy)aniline was administered by gavage at two doses of 10 mg / kg / day and 20 mg / kg / day for three consecutive days.
[0059] 2. Experimental modeling
[0060] On the second day, 10 mg / kg LPS was injected intraperitoneally 2 hours after oral administration. Twelve hours later, lung tissues were collected and fixed in 4% paraformaldehyde at room temperature for one day. HE staining was performed to observe lung pathological changes, and photos were taken with an ECHO inverted and upright microscope.
[0061] 3. Experimental results
[0062] HE staining results Figure 6 As shown in the figure, the alveolar epithelial cells in the lung tissue of the control group were arranged in an orderly manner with neat structure, and there was no alveolar interstitial edema, alveolar wall thickening and inflammatory cell infiltration. Compared with the control group, the alveolar wall in the model group was significantly thickened, with infiltration of neutrophils and monocytes, accompanied by alveolar edema and alveolar congestion. Dexamethasone (DXM) as a positive control can significantly inhibit LPS-induced lung pathological damage. At the same time, 10 mg / kg and 20 mg / kg of 2-(2-methylpropoxy)aniline can effectively inhibit alveolar wall thickening, inflammatory cell infiltration and interstitial edema.
[0063] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for a person skilled in the art to modify the technical solutions described in the aforementioned embodiments, or to replace some of the technical features therein with equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions claimed to be protected by the present invention.
Claims
1. Application of 2-(2-methylpropoxy)aniline in the preparation of drugs for treating inflammatory diseases.
2. The use according to claim 1, It is characterized in that The 2-(2-methylpropoxy)aniline can significantly inhibit the release of inflammatory mediator NO.
3. The use according to claim 2, It is characterized in that The 2-(2-methylpropoxy)aniline can effectively inhibit the release of the inflammatory mediator NO in a dose-dependent manner within the range of 10 μM to 40 μM.
4. The use according to claim 1, It is characterized in that The 2-(2-methylpropoxy)aniline can effectively inhibit LPS-induced macrophage M1 polarization and thus exert an anti-inflammatory effect.
5. The use according to claim 4, It is characterized in that The 2-(2-methylpropoxy)aniline can effectively reduce the mRNA transcription levels of M1 macrophage polarization markers CD86 and CD80.
6. The use according to claim 1, It is characterized in that The 2-(2-methylpropoxy)aniline can significantly inhibit the transcription levels of iNOS and COX-2 and the protein expressions of the key inflammatory enzymes iNOS and COX-2.
7. The use according to claim 1, It is characterized in that The 2-(2-methylpropoxy)aniline can significantly reduce the expression levels of pro-inflammatory factors TNF-α, IL-6, IL-1β, and IFN-β.
8. The use according to claim 1, It is characterized in that The inflammatory diseases include acute lung injury, pneumonia, and sepsis.
